trending Market Intelligence /marketintelligence/en/news-insights/trending/8yu42afjbe4h_yw_xvszda2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Hybrigenics completes genomics unit buyout as part of strategic shift

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Hybrigenics completes genomics unit buyout as part of strategic shift

Hybrigenics SA completed the previously announced buyout of its unit Helixio, which provides genomic services, by its employees and managers.

Financial terms of the transaction were not disclosed.

The buyout is part of Hybrigenics' strategic refocusing on biopharmaceutical research and development, particularly on anti-cancer drugs. Following the transaction, the Paris-based company and Helixio will operate as fully independent entities.